β-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 774-779

  Ozasa, Neiko ^a   Morimoto, Takeshi ^b   Bao, Bingyuan ^a   Furukawa, Yutaka ^c   Nakagawa, Yoshihisa ^d   Kadota, Kazushige ^e   Iwabuchi, Masashi ^f   Shizuta, Satoshi ^a   Shiomi, Hiroki ^a   Tazaki, Junichi ^a   Natsuaki, Masahiro ^a   Kimura, Takeshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^d TENRI HOSPITAL   (Japan)

^e KURASHIKI CENTRAL HOSPITAL   (Japan)

^f KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Coronary artery disease; Percutaneous coronary intervention; Prognosis; blocker

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REGISTER; RISK ASSESSMENT;

CORONARY ARTERY DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; Β-BLOCKER;

ADRENERGIC BETA-ANTAGONISTS; AGED; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; TREATMENT OUTCOME;

EID: 84885313935     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.001     Document Type: Article

References (20)

1. Fraker Jr TD, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for themanagement of patientswith chronic stable angina. Circulation 2007;116: 2762-72.
2. Bunch TJ, Muhlestein JB, Bair TL, et al. Effect of β-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure. Am J Cardiol 2005;95:827-31.
3. Frishman WH. Multifactorial actions of β-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation 1983;67:I11-8.
4. Kimura T, Morimoto T, Furukawa Y, et al. Long-termsafety and efficacy of sirolimuseluting versus bare-metal stents in real world clinical practice in Japan. Cardiovasc Interv Ther 2011;26:234-45.
5. Serruys PW, Ong ATL, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease -the final analysis of the arterial revascularization therapies study (ARTS) randomized trial. J Am Coll Cardiol 2005;46:575-81.
6. Ghali WA, Quan H, Brant R, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-7.
7. Kendall MJ. Clinical relevance of pharmacokinetic differences between β blockers. Am J Cardiol 1997;80:15J-9J.
8. Parsons LS. Reducing bias in a propensity score matched pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc.; 2001.
9. Wang TJ, Stafford RS. National patterns and predictors of β-blocker use in patients with coronary artery disease. Arch Intern Med 1998;158:1901-6.
10. Kohro T, Hayashi D, Yamazaki T, Nagai R. βeta-blocker prescription among Japanese cardiologists and its effect on various outcomes. Circ J 2010;74:962-9.
11. Maddox TM, Ho PM, RoeM, Dai D, Tsai TT, Rumsfeld JS. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Circ Cardiovasc Qual Outcomes 2010;3:632-41.
12. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43.
13. Natsuaki M, Furukawa Y, Morimoto T, et al. Intensity of statin therapy, achieved LDL-C levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Circ J 2012;76:1369-79.
14. The Japanese Beta-blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004;93:969-73.
15. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
16. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
17. Bangalore S, Sawhney S, Messerli FH. Relation of β-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9.
18. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
19. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
20. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to β-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002;40:1589-95.